SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-20-004697
Filing Date
2020-03-25
Accepted
2020-03-25 16:02:28
Documents
53
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 1381414
2 ex4-1.htm EX-4.1 28219
3 ex-31.htm EX-31 12613
4 ex-32.htm EX-32 6738
  Complete submission text file 0001493152-20-004697.txt   3936721

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE lixt-20191231.xml EX-101.INS 465729
6 XBRL SCHEMA FILE lixt-20191231.xsd EX-101.SCH 51468
7 XBRL CALCULATION FILE lixt-20191231_cal.xml EX-101.CAL 34483
8 XBRL DEFINITION FILE lixt-20191231_def.xml EX-101.DEF 150522
9 XBRL LABEL FILE lixt-20191231_lab.xml EX-101.LAB 319842
10 XBRL PRESENTATION FILE lixt-20191231_pre.xml EX-101.PRE 218055
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE
Type: 10-K | Act: 34 | File No.: 000-51476 | Film No.: 20742201
SIC: 2834 Pharmaceutical Preparations